

LSE FORUM

In collaboration with AstraZeneca

on

Evidence for Approval and Access to New Oncology Medicines: Today's Challenges and Tomorrow's Solutions

Thursday 28 November 2019, 13:00–18:30

The Lincoln Centre, 18 Lincoln's Inn Fields, London WC2A 3ED

On 28 November 2019, the LSE Forum “**Evidence for approval and access to new oncology medicines: Today's challenges and tomorrow's solutions**” took place at The Lincoln Centre in London. The event was organised by LSE Health in collaboration with AstraZeneca and was funded by AstraZeneca.

The purpose of the Forum, which was chaired by Professor David Taylor, Professor Emeritus, School of Pharmacy, University College London (UCL), was to debate issues around value, innovation and access to innovative therapies, with a particular focus on oncology. Specifically, the two panels of the Forum discussed (a) LSE's research on the interrelationship between accelerated approval schemes for oncology medicines and national HTA processes across 7 OECD countries; and (b) the challenges of assessing value of cancer therapies in an earlier disease setting.

Each panel was structured around a 20 minute keynote presentation based on research conducted, followed by brief reactions and comments from select panellists, representing perspectives from academia, health technology assessment (HTA) agencies, the health care system, industry and the patient community, followed by a general discussion with participants.

Panel 1: The impact of HTA on access to oncology medicines approved through accelerated access pathways

Panel 1 discussed the impact of HTA on access to oncology medicines approved through accelerated access pathways and the keynote presenter was Dr Panos Kanavos, Deputy Director, LSE Health & Associate Professor, Department of Health Policy. The presentation was based on key findings from research on HTA and reimbursement decision-making of products with accelerated approval. The presentation was followed by a 30-minute panel discussion moderated by the Forum Chair, Professor David Taylor.

Interventions were made by the following experts:

- Professor Michael Drummond, Professor of Health Economics, University of York
- Professor John Hutton, Emeritus Professor of Economics, University of York
- Dr Olivier Wong, Chief Medical Officer, Medi-Qualité Omega
- Duncan Sim, Policy Adviser, Cancer Research UK
- Dr Serban Ghiorghiu, Vice President, Clinical Development, Oncology, AstraZeneca

To see the recordings of Panel 1, please click on the links below:

- [Panel 1 Presentation](#)
- [Panel 1 Discussion](#)

Panel 2: The value of innovation in early disease

Panel 2 discussed how innovation is valued in early disease and the main presenter was Dr Chris Abbosh, Medical Oncology Registrar and Fellow, UCL Hospital and Francis Crick Institute. The presentation was followed by a 30-minute panel discussion moderated by the Forum Chair, Professor David Taylor.

Interventions were made by the following experts:

- Professor Michael Drummond, Professor of Health Economics, University of York
- Professor Eva Susanne Dietrich, Head of the Institute for Evidence Based Positioning in the Healthcare Sector, Germany
- Jean Mossman, Senior Associate, Medical Technology Research Group, London School of Economics and previously Chief Executive, Cancer BACUP
- Dr Greg Rossi, Vice President, DDR Franchise and Oncology Market Access and Pricing, AstraZeneca

To see the recordings of Panel 2, please click on the links below:

- [Panel 2 Presentation](#)
- [Panel 2 Discussion](#)

The event provided a unique opportunity to bring together clinical expertise, technical innovation and scientific thinking to discuss the latest developments on access to innovative oncology therapies, the impact of accelerated access pathways and the role of HTA, valuing innovation in early stage disease as well as debate recent challenges and explore future prospects. It was attended by a number of stakeholders from the UK and Europe, including policy makers, health economists, payers, policy makers, industry representatives and patient advocacy groups. The Forum was also livestreamed globally.